Shared autonomic phenotype of long COVID and myalgic encephalomyelitis/chronic fatigue syndrome

Peter Novak; David M. Systrom; Alexandra Witte; Sadie P. Marciano; Donna Felsenstein; Jeff M. Milunsky; Aubrey Milunsky; Joel Krier; Mark C. Fishman

doi:10.1371/journal.pone.0341278

Abstract

Introduction

Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are relatively common and disabling multisystem disorders that share overlapping features, including post-infectious onset and similar clinical manifestations such as brain fog, fatigue, muscle pain, and dysautonomia with orthostatic intolerance. These similarities suggest that Long COVID and ME/CFS may share common pathophysiological mechanisms, though the underlying mechanisms remain poorly understood, partly due to the difficulty in quantifying many of the symptoms.

Materials and methods

This retrospective study evaluated Long COVID and pre-COVID ME/CFS patients who completed autonomic testing between 2018 and 2023 at the Brigham and Women’s Faulkner Hospital Autonomic Laboratory. The evaluations included autonomic tests (Valsalva maneuver, deep breathing, tilt-table test, and sudomotor function) with capnography and transcranial Doppler monitoring of cerebral blood flow velocity (CBFv) in the middle cerebral artery, neuropathic assessment through skin biopsies for small fiber neuropathy (SFN), invasive cardiopulmonary exercise testing (ICPET), and laboratory analyses covering metabolic, inflammatory, autoimmune, and hormonal profiles.

Results

A total of 143 Long COVID and 170 ME/CFS patients were analyzed and compared to 73 healthy controls and 290 patients with hypermobile Ehlers-Danlos syndrome (hEDS). Tests revealed extensive similarities between Long COVID and ME/CFS, including reduced orthostatic CBFv (92%/88% in Long COVID/ME/CFS), mild-to-moderate widespread autonomic failure (95%/89%), presence of SFN (67%/53%), postural tachycardia syndrome (POTS) (22%/19%), neurogenic orthostatic hypotension (15%/15%) and preload failure (96%/92%, assessed in 25/66 Long COVID/ME/CFS). Patients with hEDS exhibited more severe peripheral neurodegeneration compared to the other groups. Laboratory tests did not distinguish between the conditions.

Conclusion

Both Long COVID and ME/CFS demonstrate dysregulation in cerebrovascular blood flow, autonomic reflexes, and small fiber neuropathy, suggesting that these conditions may share a common underlying pathophysiology. However, differing distributions of findings in patients with hEDS raise the question of whether these conditions represent distinct but overlapping syndromes or reflect a shared underlying pathway. Further research is required to clarify the relationship between these conditions and the potential underlying pathophysiological mechanisms.

Citation: Novak P, Systrom DM, Witte A, Marciano SP, Felsenstein D, Milunsky JM, et al. (2026) Shared autonomic phenotype of long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. PLoS One 21(1): e0341278. https://doi.org/10.1371/journal.pone.0341278

Editor: Hong-Liang Zhang, First Hospital of Jilin University, CHINA

Received: February 26, 2025; Accepted: January 4, 2026; Published: January 23, 2026

Copyright: © 2026 Novak et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: Data sharing will follow Data Sharing Policy of Mass General Brigham (MGB). In accordance with MGB policy [1], a Data Use Agreement (DUA) is required prior to any exchange of human subject data with an external party for research purposes. Principal Investigators (PIs) are responsible for ensuring that the appropriate approvals are in place before any data is shared. Specifically, the PI must consult with the Institutional Review Board (IRB) to determine the necessary type and level of IRB review applicable to the proposed research involving MGB data. No data may be shared until all institutional and regulatory requirements have been met. For questions related to IRB requirements, the IRB office may be contacted at IRB@mgb.org. For assistance with DUA templates or modifications, or to submit finalized documents, contact RMDUA@mgb.org. A copy of the signed DUA and signed attestation will be submitted to RMDUA@mgb.org as required. For more information, please refer to the MGB Data Sharing Policy: https://partnershealthcare.sharepoint.com/sites/phrmInitiate/imcdc/Pages/Data-Use-Agreements-(DUAs).aspx 1: Data Sharing Policy at Mass General Brigham: ‘https://partnershealthcare.sharepoint.com/sites/phrmInitiate/imcdc/Pages/Data-Use-Agreements-(DUAs).aspx’.

Funding: This work was funded by Mona Taliaferro/Bay Shore Recycling, The National Heart, Lung and Blood Institute (NHLBI - 1OT2HL156812-01) and FBRI LLC (2022A018462) to P. Novak. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Dr. Novak is an advisor - independent Contractor for Dysimmune Diseases Foundation. Dr. Novak is a member of the Scientific Advisory Board of Endonovo Therapeutics. Dr. Novak received royalties from Oxford University Press.PN is a current or previous shareholder of Moderna, and Pfizer.

Introduction

Postacute sequelae of SARS-CoV-2, also known as Long COVID, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are complex, multisystem disorders that significantly overlap in clinical presentation [1–6]. Approximately 10%−60% of individuals who have suffered for SARS-CoV-2 infection continue to experience or develop new symptoms consistent with Long COVID [7–9]. About 10%−80% of ME/CFS patients report preceding viral infection, mostly associated with the Epstein-Barr virus [10,11]. Both disorders are frequently disabling, and significantly impair daily functioning. Typical symptoms associated with both disorders include persistent fatigue, cognitive problems including brain fog, headaches, unrefreshing sleep, muscle and joint pain, post-exertional malaise, orthostatic intolerance, gastrointestinal symptoms and a variety of other symptoms [1,6]. While numerous abnormalities in immunologic, bioenergetics, and physiologic domains have been identified, the findings remain heterogenous, particularly within ME/CFS research and reliable biomarkers for both conditions have yet to be developed [4,11].

The pathophysiological mechanisms underlying both disorders remain incompletely understood. However, the overlapping symptomatology and frequent temporal association with antecedent infections raise the possibility of shared or converging biological pathways [4,6,12]. Emerging evidence increasingly implicates autonomic nervous system dysfunction as a common feature of both conditions [1]. Dysregulation of both the sympathetic and parasympathetic branches—manifesting as postural orthostatic tachycardia syndrome (POTS), orthostatic hypotension, autonomic failure and broader altered cardiac autonomic regulation has been implicated [13–15]. Impaired cerebral blood flow associated with or due to autonomic dysfunction may also be a common feature of both conditions [16]. Additionally, small fiber neuropathy (SFN) has been investigated as a potential underlying pathological substrate contributing to peripheral autonomic impairment [17,18].

In this study, we conducted a comparative analysis of Long COVID and ME/CFS using comprehensive assessment of cerebrovascular blood flow, autonomic reflexes, skin biopsies and metabolic, inflammatory, autoimmune, and hormonal profiles. These measurements were compared to historical healthy controls (excluding laboratory blood work data) and patients with hypermobile Ehlers-Danlos syndrome (hEDS), a heritable connective tissue disorder commonly associated with dysautonomia [19].

The underlying hypothesis tested was that Long COVID and ME/CFS share similar pathophysiology, and as a result, their key findings should be similar. By including hEDS as a disease control with a different etiology, we also evaluated whether the observed findings represent a common physiological response to illness or if they are specific to Long COVID and ME/CFS.

Materials and methods

This retrospective, single-center study evaluated consecutive adult patients with a diagnosis of Long COVID, ME/CFS, and hEDS who underwent autonomic testing between January 1, 2018 and December 31, 2023 at the Brigham and Women’s Faulkner Hospital Autonomic Laboratory, Boston, for evaluation of orthostatic intolerance. Clinical data were obtained from patients’ electronic records. Data for research purposes were accessed on May 14, 2023 and on January 2, 2025.

Standard protocol approvals, registrations, and patient consent

The study was approved by the Institutional Review Board of the Brigham and Women’s Hospital, Harvard University, as a minimal-risk study, and the consent form signature was waived. Authors of the study had access to information that could identify individual participants during data collection.

Clinical definitions

Orthostatic intolerance was defined as the presence or exacerbation of chronic (>6 months) symptoms attributable to cerebral hypoperfusion – such as lightheadedness, dizziness, dyspnea, brain fog, fatigue and visual disturbances – upon assuming an upright posture, with a partial or complete relief of symptoms upon recumbency. POTS was defined as a combination of orthostatic intolerance and an increment in heart rate ≥ 30 beats per minute for ages > 19 years and 40 beats per minute for ages 18–19 years without orthostatic hypotension during the tilt test [20]. Hypocapnic cerebral hypoperfusion (HYCH), was defined as a combination of orthostatic intolerance and reduced orthostatic cerebral blood flow velocity (CBFv) associated with hypocapnia (end-tidal CO₂< 30 mmHg [21]), but without orthostatic tachycardia or orthostatic hypotension [22]. Orthostatic cerebral hypoperfusion syndrome (OCHOS) was defined by reduced orthostatic CBFv without orthostatic hypotension, orthostatic tachycardia and orthostatic hypocapnia [23].

Inclusion and exclusion criteria

Inclusion criteria.

Adults aged >18 years, both men and women, who completed autonomic testing and had a documented history of Long COVID and ME/CFS. Long COVID diagnosis was based on the following: 1) Evidence of previous SARS-CoV-2 infection—established by a history of acute illness (characterized by fever, cough and malaise) and confirmed by a positive SARS-CoV-2 test (either antigen or polymerase chain reaction). 2) Symptoms linked to Long COVID. Long COVID is a heterogenous condition, and at the time the study was performed, the exact diagnostic criteria were still evolving [7]. Long COVID was defined as a constellation of persistent, relapsing or new symptoms after an acute infection [7,24]. These symptoms are brain fog, fatigue, smell/taste changes, post-exertional malaise, chronic cough, thirst, palpitations, dizziness, and gastrointestinal symptoms at variable combinations. The study included subjects who were infected during the pre-Delta era (before June 18, 2021), the Delta era (June 19, 2021 to December 18, 2021), and the Omicron era (after December 18, 2021) [25].

The diagnosis of ME/CFS was based on myalgic encephalomyelitis international consensus criteria (ME-ICC) [26] or newer National Academy of Medicine diagnostic criteria [27]. Key features of ME/CFS are chronic, severe, disabling fatigue, post-exertional malaise, brain fog, sleep disturbances such as unrefreshing sleep, variable pain syndromes, and orthostatic intolerance.

The Long COVID and ME/CFS subjects were compared to a healthy control group from our autonomic research database at the University of Massachusetts [28]. All healthy controls were asymptomatic and had normal responses to tilt in heart rate, blood pressure, CBFv and respiratory variables.

We compared the Long COVID and ME/CFS patients to those with hypermobile Ehlers-Danlos syndrome (hEDS), all of whom were evaluated in our laboratory using the same methodology. hEDS is a genetic disorder of connective tissue that is frequently associated with dysautonomia [29]. Unlike Long COVID and ME/CFS, there is no evidence implicating infection in the pathogenesis of hEDS. Key features of hEDS include joint hypermobility, variable pain syndromes, hyperextensible skin, and autonomic dysfunction [29].

Diagnosis of hEDS was based on the Beighton-Villefranche criteria for patients seen prior to 2017) [30], and on the 2017 international criteria thereafter [31]. All hEDS diagnoses and were made by genetic specialists (JK, AM, or JM). The Beighton-Villefranche criteria do not distinguish between hEDS and hypermobile spectrum disorders, the latter being considered a milder form of hEDS [31]. Therefore, diagnoses made prior to 2017 were retrospectively confirmed using the updated international criteria.

Exclusion criteria.

We excluded patients with hEDS who had a concurrent diagnosis of chronic fatigue [19] or met the diagnostic criteria for ME/CFS. Additionally, patients who did not complete or were unable to tolerate autonomic testing were excluded.

Patient reported surveys

Patient-reported surveys were done as a part of autonomic testing. The Survey of Autonomic Symptoms (SAS) was used to assess the frequency and severity of autonomic symptoms [32]. The cutoff point > 7 in the SAS score was considered to be clinically significant. Sensory complaints were assessed by the self-reported Neuropathy Total Symptom Score-6 (NTSS-6) [33]. The NTSS-6 total score > 6 was considered as clinically significant. The pain for the last seven days was assessed using the 0–10 numerical rating pain scale (0 = no pain, 10 = worst imaginable pain), a part of the NIH Toolbox [34,35]. The scores ≤ 3 correspond to mild, scores 4–6 to moderate and scores ≥7 to severe pain. Central sensitization was assessed using the central sensitization inventory (CSI), a validated instrument used for evaluation of central sensitization [36]. The score ≥ 40 was used for the diagnosis of Central Sensitization Syndrome.

Autonomic testing

All testing was performed following established standards and previously described in detail [22]. Medications that may affect autonomic function were discontinued for five half-lives or longer before the testing. Cardiovascular reflex tests included deep breathing, the Valsalva maneuver, and the tilt test. Deep breathing test was performed with inhalation and exhalation each equal to ten seconds which was repeated six times. Parasympathetic cardiovagal index was obtained as the average difference between expiratory and inspiratory heart rate. Valsalva maneuver was performed as a forced expiration at the expiratory pressure 40 mmHg for 15 seconds. The difference between baseline and end of the phase 2 in mean blood pressure was used as a sympathetic adrenergic index. Patients were tilted at 70 degrees for 10 minutes following 10 minutes of supine rest. We described details of autonomic respiratory and cerebral blood flow measurements from the tilt previously [22].

Recorded signals included electrocardiogram, blood pressure, end-tidal CO₂, and CBFv in the middle cerebral artery using Transcranial Doppler. Blood pressure was obtained intermittently every minute by brachial sphygmomanometer using an automated monitor Welch Allyn CVSM 6400 Monitor (Skaneateles Falls, NY) and beat-to-beat using finger cuff the photoplethysmographic signal which was volume-clamped in the finger by servo control (Human NIBP Nano Interface MLA382, ADInstruments Inc., Colorado Springs, CO, USA and Human NIBP Nano Wrist Unit FMS910804, Finapress Medical Systems, Amsterdam, Netherlands). End-tidal CO₂ was obtained using Nonin Respsense Capnograph (Nonin Medical Inc. Plymouth, MN) by nasal cannula. A pulse oximeter (part of Welch Allyn monitor) was used to monitor the oxygen saturation throughout the testing.

The temporal acoustic window with a 2 MHz probe was used to acquire CBFv from the M1 segment of middle cerebral artery using a MultiDop T (Multigon, New York, NY) with an insonation depth between 45 and 65 mm. The transducer has been attached to the head using a head frame with a three-dimensional positioner. The depth and angle of insonation have been kept constant throughout the head-up tilt test. Signals were recorded using the PowerLab 16/35 data acquisition system with LabChart 8 software (ADInstruments Inc., Colorado Springs, CO, USA) and sampled at 400 Hz.

Electrochemical skin conductance (ESC) was used to measure the sudomotor function [37]. ESC correlates with loss of sweat gland nerve fibers and it is a reasonable proxy for sudomotor function [38].

Medical records were also searched for a history of invasive cardiopulmonary exercise testing (iCPET) [39] for evaluation of unexplained fatigue or dyspnea. iCPET was performed in a sitting position using a cycle ergometer as described in detail [40]. iCPET provides Fick cardiac output, right atrial pressure and previously iCPET showed impaired venous return and peripheral oxygen extraction in ME/CFS [18].

Skin biopsies

Epidermal nerve fiber density (ENFD) and sweat gland nerve fiber density (SGNFD) were obtained at the proximal thigh 20 cm distal to the iliac spine and the calf 10 cm above the lateral malleolus using a 3-mm circular punch tool. Specimen processing including immunoperoxidase staining for the axonal marker PGP 9.5, and fiber counting was done at Therapath (New York, NY) using established standards [41].

Criteria for small fiber neuropathy

SFN is defined as combination of clinical signs suggestive of small fiber dysfunction (pinprick and thermal sensory loss, allodynia, and hyperalgesia) and structural (obtained from skin biopsy) or functional (obtained from QSART or ESC) variables [37,41,42]. The following subtypes of SFN were assessed in this study: sensory SFN (abnormal ENFD, normal SGNFD), mixed SFN (abnormal ENFD and SGNFD), autonomic (normal ENFD, abnormal SGNFD), functional (abnormal electrochemical skin conductance (ESC)) and combined functional-morphological (at least one abnormal: ENFD, SGNFD, and ESC).

Grading of autonomic tests

Test results were graded using the Quantitative Scale for Grading of Cardiovascular Autonomic Reflex Tests and Small Fibers from Skin Biopsies (QASAT). QASAT is an objective instrument for grading the severity of dysautonomia, small fiber neuropathy, and cerebral blood flow abnormalities that uses normative age and gender adjusted values as appropriate. Each domain (heart rate, blood pressure, cerebral blood flow, end-tidal CO₂) is analyzed separately, where a normal score equals to 0 and the score ≥ 0 is abnormal. QASAT grading is defined as follows [22]:

Autonomic failure score (QASAT_af):

Cardiovagal failure score (QASAT_cardiovagal) is calculated from heart rate responses to deep breathing test. Adrenergic failure score (QASAT_adrenergic) is obtained as a sum of blood pressure responses to the Valsalva maneuver and head-up tilt scores. Sudomotor failure score (QASAT_sudomotor) is obtained from the ESC or QSART. The QASAT_af range is 0–22; none (0), abnormality: mild (1–3), moderate (4–12), and severe (12–22). The additional QASAT ranges are defined as follows: cardiovagal failure: none (0), abnormality: mild (1), moderate (2) and severe (3); adrenergic failure – Valsalva maneuver: none (0), abnormality: mild (1), moderate (2) and severe (3); adrenergic failure – orthostatic hypotension: none (0), abnormality: mild (1), moderate (2–5) and severe (6–10); orthostatic tachycardia: none (0), abnormality: mild (1–2), moderate (3–5) and severe (6–10); sudomotor failure – ESC: none (0), abnormality: mild (1–2), moderate (3–4) and severe (5–6); sudomotor failure – QSART: none (0), abnormality: mild (1–2), moderate (3–6) and severe (7–8); ENFD: normal (0), abnormality: mild (1–2), moderate (3–6) and severe (7–8); SGNFD: normal (0), abnormality: mild (1–2), moderate (3–6) and severe (7–8); reduced orthostatic end-tidal CO₂: normal/none (0), abnormality: mild (1–2), moderate (3–5) and severe (6–10); reduced orthostatic CBFv: normal/none (0), abnormality: mild (1–2), moderate (3–5) and severe (6–10). Details of calculations and grading of the testing were published previously [43].

Laboratory and inflammation markers

Both Long COVID and ME/CFS are postinfectious disorders were the autoimmunity and/or low grade inflammation may play a role [4]. Therefore, patient’s charts were reviewed for laboratory blood evaluations conducted during routine clinical assessments. We specifically focused on inflammatory, autoimmune, and hormonal markers, as abnormalities in these have been reported in post-infectious disorders [3,44] including: high sensitivity C-reactive protein (normative value <=3 mg/L), tumor necrosis factor-alpha (TNF-α, <= 2.8 pg/mL), interleukin (IL) IL-6 (<7.1 pg/mL), IL-10 (<2 pg/mL), IL-1ß (<7.1 pg/mL), leptin (3.3–18.3 ng/mL), trisulfated heparin disaccharide (TS-HDS) antibody (<10000) titers) [45], fibroblast growth factor receptor 3 (FGFR3) antibody (<3000 titers) [45], acetylcholine receptor binding antibody (<=0.02 nmol/L), ganglionic acetylcholine receptor antibody (<= 0.02 nmol/L) [46], neuronal VGKC antibody (<= 0.02 nmol/L), calcium channel P/Q binding antibody (<= 0.02 nmol/L), myoglobin (<=71 ng/mL) [47] and human growth hormone (0.01–3.61 ng/mL) [47]. We also measured supine (70–750 pg/mL) and standing (200–1700 pg/mL) plasma norepinephrine levels, as these values are useful in assessing the hyperadrenergic form of POTS [20]. The systemic immune-inflammation index defined as neutrophils x platelets/lymphocytes was shown to be useful predictor marker in several malignances [48] was calculated as well.

TS-HDS and FGFR3 antibodies were obtained from Washington University School of Medicine (St. Louis, MO), remaining antibodies as well as TNF-α, IL-10, human growth hormone were obtained from Mayo Clinic laboratories (Rochester, MN). IL-6 was obtained at Mayo Clinic laboratories (Rochester, MN) or at BWH Clinical laboratories (Boston, MA). IL-1ß was obtained at Sunquest (Tucson, AZ). Leptin was obtained at Esoterix Endocrinology (Calabasas Hills, CA). Remaining of laboratory tests were obtained at BWH Clinical laboratories (Boston, MA) or at Quest Diagnostics (Secaucus, NJ).

Statistical analysis

The continuous data were not normally distributed, and outliers were present. Additionally, the groups failed to meet the assumption of homogeneity of variances. We chose not to remove the outliers, as they may carry clinically important information, and their removal could significantly alter the data distribution. Therefore, we used the nonparametric Kruskal-Wallis test to compare the groups, as it does not assume a normal distribution and is relatively robust to outliers and heterogeneity of variances particularly in large datasets [49]. The effect of size was measured by epsilon squared. If an overall comparison was statistically significant, pairwise post hoc comparisons were performed using Dunn test [50] with the Benjamini-Hochberg adjustment for multiple comparisons [51]. For categorical data, overall comparisons across groups were conducted using the Chi-squared as it does not assume normality [52]. If an overall comparison was statistically significant, pairwise post hoc comparisons were performed using the Fisher’s Exact Test with Holm adjustment for multiple comparisons [53].

The effect of head-up tilt on hemodynamic variables was assessed using the linear mixed-effects models adjusted for supine baseline and with a random intercept with repeated-measures design [54]. The predictor variables were the diagnosis and position of the subjects (supine versus upright, minutes 1–10). Gender and age were covariates.

The relationship between lightheadedness during head-up tilt (absent versus present) and QASAT domains was evaluated using the binary logistic regression model.

A higher proportion of missing values was expected in the laboratory blood work, likely due to test ordering being at the discretion of the attending physicians. Ignoring missing data could affect the robustness of our findings. Assuming the data were missing at random, we conducted a sensitivity analysis to assess the potential impact. Specifically, we compared the results of the Kruskal–Wallis test for continuous variables across three scenarios: (1) complete-case analysis using the original dataset with missing data ignored, (2) imputation using the overall mean, and (3) imputation using the overall median.

The R software (www.r-project.org) was used for statistical analyses.

Statistical power

The sample size for this study was determined based on a power analysis appropriate for detecting differences among four independent groups using the Kruskal-Wallis test, a nonparametric method suitable for non-normally distributed data. Assuming an alpha level of 0.05 and a desired statistical power of 0.80, the analysis utilized a logistic distribution to approximate the underlying data characteristics. For the primary outcome variable (total QASAT value), based on preliminary estimates of the mean and standard deviation, the minimal sample size required for each group was determined to be 37.2.

Results

Of the total number of consecutive patients referred for autonomic testing with diagnoses of Long COVID (n = 166), ME/CFS (n = 203), and hEDS (n = 352), a subset was excluded due to incomplete or missing data (Fig 1). Ultimately, 143 patients with Long COVID and 170 with ME/CFS—predominantly younger women—were included in the study. These groups were compared to 73 healthy controls and 290 consecutive patients with hEDS (Table 1).

Download:

Table 1. Demographic and baseline characteristics.

https://doi.org/10.1371/journal.pone.0341278.t001

Download:

Fig 1. Flow chart of the study.

https://doi.org/10.1371/journal.pone.0341278.g001

From Long COVID patients, 6 were of pre-Delta era, 10 of Delta era and remaining were Omicron era. All ME/CFS and hEDS patients were diagnosed before the onset of SARS-CoV-2 pandemics.

Long COVID and ME/CFS patients had similar age and gender, but Long COVID had a higher body mass index (BMI, p = 0.006)) and shorter (p < 0.001) symptom duration defined as the length of time since disease onset. Co-morbidities and medications were similar, but fibromyalgia (p = 0.01), chronic Lyme disease (p = 0.004), and the use of pressor medications (p < 0.001) were more frequent in ME/CFS. Compared to Long COVID and ME/CFS, hEDS patients were younger (p < 0.001), had more frequent mast cell activation syndrome (p < 0.001), irritable bowel syndrome (p = 0.03), more pain (p < 0.01), headaches (p < 0.00) and treatment with antihistamine medications (p < 0.01). Laboratory evaluations that comprised of a spectrum of metabolic, hormonal, blood, inflammatory and autoimmune markers, available only in a subset of patients, were unrevealing, mostly within the normal range, and were similar between the Long COVID and ME/CFS and hEDS.

The sensitivity analysis showed that missing values did not significantly affect the robustness of our results.

Symptoms

Long COVID and ME/CFS had a similar degree of complaints in the autonomic (total and subtotal scores on SAS), neuropathic (NTSS-6), pain, and central sensitization domains (Table 2). hEDS group had worse most of the SAS and NTSS-6 scores, and some central sensitization scores (pain, stiffness) (p = 0.05- < 0.001).

Download:

Table 2. Patient’s reported outcome measures.

https://doi.org/10.1371/journal.pone.0341278.t002

Autonomic testing

Cardiovascular, cerebrovascular and respiratory variables at supine baseline and during the head-up tilt are shown in the Table 3 and Fig 2A–2D. Comparing all groups in the supine position, there was a significant difference in deep breathing, blood pressure response in the Valsalva maneuver, and ENFD (p < 0.001–0.03) but the difference was not significant in pair-wise comparisons. Furthermore, ESC was higher in hEDS compared to ME/CFS (p = 0.008), and Long COVID (p < 0.001). ENFD at the calf and SGNFD at the proximal thigh were higher in ME/CFS as compared to Long COVID (p = 0.043) and hEDS (p = 0.049). SGNFD was lower in hEDS compared to ME/CFS (p = 0.007). End-tidal CO₂ supine (p = 0.004) and orthostatic (p < 0.001) were lower in Long COVID.

Download:

Table 3. Results of autonomic testing.

https://doi.org/10.1371/journal.pone.0341278.t003

Download:

Fig 2. The head-up tilt profile showing hemodynamic variables at supine baseline and at every minute of head-up tilt, expressed as mean±sd.

A: heart rate; B: mean blood pressure; C: mean cerebral blood flow velocity in the middle cerebral artery (CBFv); D: end-tidal CO₂. *Denotes overall p value calculated by ANOVA.

https://doi.org/10.1371/journal.pone.0341278.g002

The head-up tilt responses are shown in Fig 2A–2D as minute-by-minute profiles of cardiovascular, cerebrovascular and respiratory variables at rest and during the 10-minute head-up tilt. The patients with Long COVID and ME/CFS had similar heart rate and blood pressure increases during tilt (Fig 2A, 2B), reduced CBFv with a greater than 22% decline from baseline (Fig 2C), and end tidal CO₂ (Fig 2D). There was no difference for all tested variables between Long COVID and ME/CFS, except orthostatic end-tidal CO₂ was lower in the Long COVID group (p < 0.001). The hEDS group had a higher heart rate during tilt (p < 0.03) (Fig 2, Table 3), and higher orthostatic CBFv (p < 0.001) and lower cerebrovascular resistance as compared to Long COVID and ME/CFS. In all subjects, the oxygen saturation was within normal limits throughout the testing (range 96–99%).

Linear model showed significant effect of the diagnoses on the tilt responses for all hemodynamic variables (p < 0.001, Fig 2).

QASAT

Overall comparisons showed abnormal QASAT scores (>0) in all domains in both groups, indicating mild-to-moderate dysautonomia. Fig 3A–3C and Tables 3 and 4 show absolute QASAT values, % of normalized scores, and frequency of abnormal findings. Both the Long COVID and ME/CFS groups had a worse QASAT_sudomotor score compared to the hEDS group (Figs 3A, 2B).

Download:

Table 4. Frequency of abnormal findings.

https://doi.org/10.1371/journal.pone.0341278.t004

Download:

Fig 3. QASAT results.

(A) Absolute scores, mean±sd. (B) Normalized scores in percent, mean±sd.int. (C) Percentage of patients in which the QASAT score was abnormal (> 0). CBFv = cerebral blood flow velocity, ET-CO₂ = end-tidal CO₂, AF = autonomic failure; OT = orthostatic tachycardia (orthostatic heart rate increment ≥ 30 BPM); Sudo = sudomotor; OH = orthostatic hypotension; SFN = small fiber neuropathy; ENFD = epidermal nerve fiber density, SGNFD = sweat gland nerve fiber density, SFN-any-b = small fiber neuropathy detected on skin biopsy defined as abnormal ENFD or SGNFD, SFN-any-b + s = small fiber neuropathy detected on skin biopsy or sudomotor testing.

https://doi.org/10.1371/journal.pone.0341278.g003

Orthostatic lightheadedness was observed in >65% of patients, but orthostatic dyspnea was reported only in 21% of Long COVID patients, 37% of ME/CFS patients, and 28% of hEDS patients (Table 4). Tests revealed extensive similarities between Long COVID and ME/CFS, including reduced orthostatic CBFv (80%/92% Long COVID/ME/CFS), mild-to-moderate widespread autonomic failure (89%/95%), presence of SFN (63%/67%), postural tachycardia syndrome (32%/22%) and neurogenic orthostatic hypotension (12%/17%).

Small fiber neuropathy affected ~80–90% of patients using combined morphological and functional criteria. In Long COVID, QASAT_ENFD was abnormal in 48.3% compared to 33.5% in ME/CFS (p = 0.02), but QASAT_SGNFD 27.8% was similar to ME/CFS 28.8%. The rate of SFN (from any biopsy) was similar between Lon COVID 67.2% and hEDS 63.3%,but was higher than in ME/CFS 52.6% (p = 0.04).

Invasive cardiopulmonary exercise testing (iCPET)

iCPET was done in a sitting position, and the results were available in 25 Long COVID and 66 ME/CFS (Table 5). Unadjusted resting stroke volume (Long COVID vs. ME/CFS: p = 0.01), exercise stroke volume (p = 0.01), cardiac output (p = 0.003), and oxygen uptake (p = 0.001) were higher in Long COVID; however, these differences were no longer significant after adjusting for BMI (which was higher in Long COVID). Preload failure was detected in 96% of Long COVID and 92.4% of ME/CFS patients. Deconditioning was present in 64% of Long COVID and ME/CFS patients.

Download:

Table 5. Invasive Cardiopulmonary exercise test results.

https://doi.org/10.1371/journal.pone.0341278.t005

Discussion

We report here central sensitization, cerebrovascular, dysautonomic, and neurodegenerative attributes of Long COVID and ME/CFS which are shared among the vast majority of patients with these disorders.

Comparing Long COVID with ME/CFS

Long COVID and ME/CFS are associated with central sensitization and abnormalities in multiple domains including cerebral blood flow and respiratory dysregulation, small fiber neuropathy, and widespread autonomic failure. Table 6 provides a quantitative summary of main difference between Long COVID and ME/CFS.

Download:

Table 6. Results summary showing differences Long COVID vs. ME/CFS.

https://doi.org/10.1371/journal.pone.0341278.t006

Central sensitization

Evidence of central sensitization was frequently observed in the majority of our patients. Central sensitization refers to the increase responsiveness of the nervous system to stimuli and is linked to abnormal interoception [55–57]. The features of central sensitization such as chronic pain, brain fog, fatigue and autonomic complaints has been documented in a variety of pain and fatigue-related syndromes, including [55], long COVID [58], hEDS [59], and chronic fatigue syndrome [56]. Our study confirmed a high prevalence of central sensitization in Long COVID (78.1%), ME/CFS (85.4%), and hEDS (92.4%). The high prevalence of central sensitization in these conditions likely contributes to the significant symptoms burden experienced by patients.

Cerebral blood flow

In both Long COVID and ME/CFS, orthostatic CBFv was reduced, due either to abnormal cerebral autoregulation (consistent with OCHOS) or due to hypocapnia-induced cerebral arteriolar vasoconstriction (consistent with POTS and HYCH). Long COVID patients had more frequent orthostatic cerebral blood flow abnormalities and a greater decline in orthostatic cerebral blood flow than ME/CFS patients. Orthostatic hypotension did not play a significant role, because it was only detected in a few patients and orthostatic blood pressure remained in an autoregulatory range.

Reduced CBFv and associated cerebral hypoperfusion may explain some of the disabling symptoms of Long COVID and ME/CFS, such as lightheadedness, brain fog, and chronic fatigue. Previous studies have shown correlations between declines in orthostatic CBFv and lightheadedness [60], a key symptom of cerebral hypoperfusion. Typically a reduction in orthostatic CBFv by 19% or more from the supine baseline is associated with symptoms of central nervous system dysfunction [61,62]. Both our patient groups exceeded that level of decline (Long COVID −25% and ME/CFS −22%). In addition to the reduction of cerebral blood flow, respiratory alkalosis associated with hypocapnia changes neuronal excitability and may alter brain activity [63,64]. Imaging studies using arterial spin labeling showed reduced cerebral blood flow in COVID-19 patients [65,66]. Cerebral hypoperfusion consistent with a large resting state central network dysfunction was detected in Long COVID [67]. Cerebral blood flow dysregulation is also present in hEDS although the abnormality is less severe compared to Long COVID and ME/CFS patients.

Autonomic features

Our study detected frequent autonomic failure in both Long COVID (95%) and ME/CFS (89%). Autonomic failure was widespread, affecting cardiovagal, adrenergic, and sudomotor domains. While the cardiovagal and adrenergic abnormalities were mild, sudomotor abnormalities were moderate. Although the dysautonomia tended to be worse in Long COVID compared to ME/CFS, the pattern was similar, affecting multiple domains simultaneously.

Orthostatic intolerance associated with autonomic dysregulation has been observed in both Long COVID and ME/CFS, although the reports are inconsistent [15]. In ME/CFS, most spectral analysis studies showed decreased heart rate variability with reduced parasympathetic and sympathetic activity, with increasing the sympathetic/parasympathetic ratio [13] that was interpreted as relative sympathetic overactivity, although that interpretation is debated [68]. Another study found baroreflex failure with vagal efferent defect derived from analysis of blood pressure variability [15]. Yet another study found no difference in objective autonomic testing compared to chronic fatigue and controls [69]. The variability in findings can be attributed to the heterogeneity of ME/CFS, along with differences in inclusion criteria and techniques for the evaluation. Mild autonomic abnormalities have been detected in Long COVID patients [3,70–73]. This current study confirmed our previous finding [3,73] and expanded the analysis to the ME/CFS group. Due to the small number of pre-Omicron cases, we did not perform a comparative analysis of the effects of different SARS-CoV-2 strains.

iCPET also showed similarities between Long COVID and ME/CFS including the prevalence of preload failure (96% vs. 92.4%) and deconditioning (64% vs. 64%). Cardiac output which is proportional to BMI, was lower in ME/CFS [74]. However, the Long COVID group had a higher BMI and cardiac output adjusted for BMI was similar between the groups. Although invasive iCPET was available only in a subset of patients, the similarities in key iCPET metrics support the notion of shared common pathophysiology in both conditions.

Skin biopsies

Skin biopsies, which provide direct evidence of peripheral nerve damage, confirmed the presence of SFN in both Long COVID and ME/CFS patients. SFN was more frequently observed in individuals with Long COVID, although a similar prevalence was also noted in patients with hypermobile Ehlers-Danlos syndrome (hEDS).

Inflammatory, metabolic, and hormonal markers

We were unable to find particular features in laboratory values that would differentiate the studied disorders. Most of the subjects had normal laboratory values, and abnormal results were found in a minority of patients. There were no differences between Long COVID and ME/CFS in inflammatory, autoimmune, adrenergic, and hormonal markers. These findings are consistent with the hypothesis that both disorders may share a common pathophysiological mechanism. However, the failure to detect elevated inflammatory or autoimmune markers does not support an inflammatory or autoimmune theory for either disorder. Neverthelles, the tests used in our study may not be sensitive enough to detect low-grade inflammation. Elevated cytokines, including IL1β, IL6, and TNFα, have been reported in some, but not all, studies of Long COVID [75]. No differences were found in our study.

Furthermore, we were unable to document differences in levels of norepinephrine, a marker of adrenergic functions, which can be abnormal in peripheral dysautonomia [76]. Nevertheless, norepinephrine levels in peripheral blood do not correlate with central adrenergic activity [77]; therefore, our study cannot rule out central adrenergic dysregulation. Although hormonal dysregulation has been implicated in Long COVID [78], our study did not confirm this finding. We were unable to detect hormonal changes indicative of adrenal or hypothalamic-pituitary-adrenal axis insufficiency, as evidenced by normal cortisol and ACTH levels across our studied groups [79].

Comparisons of Long COVID/ME/CFS to hEDS

While laboratory blood evaluations were unable to distinguish among the three disorders, surveys, and autonomic functional assessments with skin biopsies revealed differentiating features. hEDS subjects reported more severe sensory and autonomic symptoms compared to Long COVID and ME/CFS. Although some overlap was observed, hEDS was associated with less severe cerebrovascular dysregulation but more pronounced peripheral neurodegeneration, as evidenced by greater sudomotor dysfunction and more frequent and severe small fiber neuropathy.

Study limitations

We are a referral center for dysautonomia, so we may not see a representative group of patients. We also used historical controls. However, the large number of patients we have studied may still provide a representative sample of these patient populations.

A limitation of direct Long COVID and ME/CFS comparison is the fact that the duration of the symptoms was much longer in ME/CFS. Duration of the disease may affect the signature of ME/CFS, particularly the immunological profile [80] which was not different between the groups. A greater prevalence of deconditioning, which would be expected with a longer-lasting ME/CFS, was also not detected in our study. Furthermore, autonomic failure was more severe in the Long COVID group, also speaking against the time effect. Nevertheless, it would be useful to longitudinally observe ME/CFS and Long COVID to determine whether these entities converge into an indistinguishable syndrome, which would provide additional evidence about the common pathophysiology of both disorders.

The lack of laboratory values in healthy controls is another study limitation. However, all laboratory tests were validated in a clinical setting, have established normative data and performed at CLIA-certified laboratories.

Methodologically, cerebral blood flow was assessed indirectly using transcranial Doppler, which measures flow velocity, and not flow directly. The velocity is proportional to blood flow, assuming that the diameter of the insonated vessel does not change during orthostatic stress, which was confirmed by an imaging study [81]. CBFv is also affected by the angle of the transcranial Doppler probe. Although the angle varies from patient to patient, once the probe was properly positioned and stabilized with a 3D holder, the same angle was maintained throughout the testing.

Conclusion

We found evidence of similar prevalence of central sensitization and similar patterns of dysregulation in cerebrovascular blood flow, respiratory and cardiovascular autonomic reflexes, and small fiber neuropathy in both Long COVID and ME/CFS. Hence, the large proportion of patients with these disorders likely lies along a spectrum with similar pathophysiology, at least as far as it concerns the cerebrovascular and autonomic nervous system, and, in principle, might benefit from similar therapeutic interventions. The ability to quantify cerebrovascular and autonomic dysfunction is helpful and it can provide the metric for therapeutic interventions. However, key findings (cerebrovascular, respiratory and cardiovascular dysregulation along with neurodegeneration) are not necessarily exclusive to Long COVID and ME/CFS since similar findings but with different distributions were found in hEDS, a condition with different cause. Further research should clarify whether these conditions share a common pathophysiological pathway or represent distinct but overlapping syndromes.

Acknowledgments

The authors thank Diana Arevalo for helping with data collection.

References

1. Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Front Med (Lausanne). 2023;10:1187163. pmid:37342500
- View Article
- PubMed/NCBI
- Google Scholar
2. Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clin Proc. 2023;98(10):1544–51. pmid:37793728
- View Article
- PubMed/NCBI
- Google Scholar
3. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, et al. Multisystem Involvement in Post-Acute Sequelae of Coronavirus Disease 19. Ann Neurol. 2022;91(3):367–79. pmid:34952975
- View Article
- PubMed/NCBI
- Google Scholar
4. Komaroff AL, Dantzer R. Causes of symptoms and symptom persistence in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. Cell Rep Med. 2025;6(8):102259. pmid:40744021
- View Article
- PubMed/NCBI
- Google Scholar
5. Powers JP, McIntee TJ, Bhatia A, Madlock-Brown CR, Seltzer J, Sekar A, et al. Identifying commonalities and differences between EHR representations of PASC and ME/CFS in the RECOVER EHR cohort. Commun Med (Lond). 2025;5(1):109. pmid:40210986
- View Article
- PubMed/NCBI
- Google Scholar
6. Wong TL, Weitzer DJ. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology. Medicina (Kaunas). 2021;57(5):418. pmid:33925784
- View Article
- PubMed/NCBI
- Google Scholar
7. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934–46. pmid:37278994
- View Article
- PubMed/NCBI
- Google Scholar
8. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med. 2022;19(11):e1004122. pmid:36355754
- View Article
- PubMed/NCBI
- Google Scholar
9. Makhluf H, Madany H, Kim K. Long COVID: Long-Term Impact of SARS-CoV2. Diagnostics (Basel). 2024;14(7):711. pmid:38611624
- View Article
- PubMed/NCBI
- Google Scholar
10. Evengård B, Jonzon E, Sandberg A, Theorell T, Lindh G. Differences between patients with chronic fatigue syndrome and with chronic fatigue at an infectious disease clinic in Stockholm, Sweden. Psychiatry Clin Neurosci. 2003;57(4):361–8. pmid:12839515
- View Article
- PubMed/NCBI
- Google Scholar
11. Walitt B, Singh K, LaMunion SR, Hallett M, Jacobson S, Chen K, et al. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nat Commun. 2024;15(1):907. pmid:38383456
- View Article
- PubMed/NCBI
- Google Scholar
12. Eckey M, Li P, Morrison B, Bergquist J, Davis RW, Xiao W. Patient-reported treatment outcomes in ME/CFS and long COVID. Proc Natl Acad Sci U S A. 2025;122(28):e2426874122. pmid:40627388
- View Article
- PubMed/NCBI
- Google Scholar
13. Nelson MJ, Bahl JS, Buckley JD, Thomson RL, Davison K. Evidence of altered cardiac autonomic regulation in myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(43):e17600. pmid:31651868
- View Article
- PubMed/NCBI
- Google Scholar
14. Ormiston CK, Świątkiewicz I, Taub PR. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. Heart Rhythm. 2022;19(11):1880–9. pmid:35853576
- View Article
- PubMed/NCBI
- Google Scholar
15. Stewart JM. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res. 2000;48(2):218–26. pmid:10926298
- View Article
- PubMed/NCBI
- Google Scholar
16. van Campen CLMC, Rowe PC, Visser FC. Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Medicina (Kaunas). 2021;58(1):28. pmid:35056336
- View Article
- PubMed/NCBI
- Google Scholar
17. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, et al. Multisystem Involvement in Post-Acute Sequelae of Coronavirus Disease 19. Ann Neurol. 2022;91(3):367–79. pmid:34952975
- View Article
- PubMed/NCBI
- Google Scholar
18. Joseph P, Arevalo C, Oliveira RKF, Faria-Urbina M, Felsenstein D, Oaklander AL, et al. Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Chest. 2021;160(2):642–51. pmid:33577778
- View Article
- PubMed/NCBI
- Google Scholar
19. Hakim A, De Wandele I, O’Callaghan C, Pocinki A, Rowe P. Chronic fatigue in Ehlers-Danlos syndrome-Hypermobile type. Am J Med Genet C Semin Med Genet. 2017;175(1):175–80. pmid:28186393
- View Article
- PubMed/NCBI
- Google Scholar
20. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72. pmid:21431947
- View Article
- PubMed/NCBI
- Google Scholar
21. Natelson BH, Intriligator R, Cherniack NS, Chandler HK, Stewart JM. Hypocapnia is a biological marker for orthostatic intolerance in some patients with chronic fatigue syndrome. Dyn Med. 2007;6:2. pmid:17263876
- View Article
- PubMed/NCBI
- Google Scholar
22. Novak P. Autonomic Testing. Oxford University Press; 2019.
23. Novak P. Orthostatic Cerebral Hypoperfusion Syndrome. Front Aging Neurosci. 2016;8:22. pmid:26909037
- View Article
- PubMed/NCBI
- Google Scholar
24. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7. pmid:34951953
- View Article
- PubMed/NCBI
- Google Scholar
25. CDC. COVID Data Tracker. In: Centers for Disease Control and Prevention [Internet]. 2020 [cited 22 Aug 2024]. Available from: https://covid.cdc.gov/covid-data-tracker
26. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270(4):327–38. pmid:21777306
- View Article
- PubMed/NCBI
- Google Scholar
27. Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clin Proc. 2021;96(11):2861–78. pmid:34454716
- View Article
- PubMed/NCBI
- Google Scholar
28. Novak P. Assessment of sympathetic index from the Valsalva maneuver. Neurology. 2011;76(23):2010–6. pmid:21646629
- View Article
- PubMed/NCBI
- Google Scholar
29. Gensemer C, Burks R, Kautz S, Judge DP, Lavallee M, Norris RA. Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. Dev Dyn. 2021;250(3):318–44. pmid:32629534
- View Article
- PubMed/NCBI
- Google Scholar
30. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet. 1998;77(1):31–7.
- View Article
- Google Scholar
31. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. pmid:28306229
- View Article
- PubMed/NCBI
- Google Scholar
32. Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology. 2011;76(12):1099–105. pmid:21422460
- View Article
- PubMed/NCBI
- Google Scholar
33. Bastyr EJ 3rd, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005;27(8):1278–94. pmid:16199253
- View Article
- PubMed/NCBI
- Google Scholar
34. Cook KF, Dunn W, Griffith JW, Morrison MT, Tanquary J, Sabata D, et al. Pain assessment using the NIH Toolbox. Neurology. 2013;80(11 Suppl 3):S49-53. pmid:23479545
- View Article
- PubMed/NCBI
- Google Scholar
35. Boonstra AM, Stewart RE, Köke AJA, Oosterwijk RFA, Swaan JL, Schreurs KMG, et al. Cut-Off Points for Mild, Moderate, and Severe Pain on the Numeric Rating Scale for Pain in Patients with Chronic Musculoskeletal Pain: Variability and Influence of Sex and Catastrophizing. Front Psychol. 2016;7:1466. pmid:27746750
- View Article
- PubMed/NCBI
- Google Scholar
36. Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing Clinically Relevant Severity Levels for the Central Sensitization Inventory. Pain Pract. 2017;17(2):166–75. pmid:26989894
- View Article
- PubMed/NCBI
- Google Scholar
37. Novak P. Electrochemical skin conductance: a systematic review. Clin Auton Res. 2019;29(1):17–29. pmid:28951985
- View Article
- PubMed/NCBI
- Google Scholar
38. Novak P. Electrochemical Skin Conductance Correlates with Skin Nerve Fiber Density. Front Aging Neurosci. 2016;8:199. pmid:27605912
- View Article
- PubMed/NCBI
- Google Scholar
39. Maron BA, Cockrill BA, Waxman AB, Systrom DM. The invasive cardiopulmonary exercise test. Circulation. 2013;127(10):1157–64. pmid:23479667
- View Article
- PubMed/NCBI
- Google Scholar
40. Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, et al. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest. 2022;161(1):54–63. pmid:34389297
- View Article
- PubMed/NCBI
- Google Scholar
41. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(Pt 7):1912–25. pmid:18524793
- View Article
- PubMed/NCBI
- Google Scholar
42. Farhad K. Current Diagnosis and Treatment of Painful Small Fiber Neuropathy. Curr Neurol Neurosci Rep. 2019;19(12):103. pmid:31773305
- View Article
- PubMed/NCBI
- Google Scholar
43. Novak P. Qpack-a Python package for QASAT-quantitative scale for grading cerebral blood flow, autonomic testing, and skin biopsies. Neurol Sci. 2022;43(8):4821–8. pmid:35347527
- View Article
- PubMed/NCBI
- Google Scholar
44. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–32. pmid:31806905
- View Article
- PubMed/NCBI
- Google Scholar
45. Levine TD, Kafaie J, Zeidman LA, Saperstein DS, Massaquoi R, Bland RJ, et al. Cryptogenic small-fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor-3. Muscle Nerve. 2020;61(4):512–5. pmid:31650561
- View Article
- PubMed/NCBI
- Google Scholar
46. Shouman K, Sandroni P. Antibody Testing for Suspected Autoimmune Autonomic Dysfunction and Small Fiber Neuropathies. J Clin Neurophysiol. 2021;38(4):274–8. pmid:34009850
- View Article
- PubMed/NCBI
- Google Scholar
47. Medic Spahic J, Ricci F, Aung N, Hallengren E, Axelsson J, Hamrefors V, et al. Proteomic analysis reveals sex-specific biomarker signature in postural orthostatic tachycardia syndrome. BMC Cardiovasc Disord. 2020;20(1):190. pmid:32321428
- View Article
- PubMed/NCBI
- Google Scholar
48. Zhong J-H, Huang D-H, Chen Z-Y. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381–8. pmid:29088873
- View Article
- PubMed/NCBI
- Google Scholar
49. Hecke TV. Power study of anova versus Kruskal-Wallis test. J Stat Manag Syst. 2012;15(2–3):241–7.
- View Article
- Google Scholar
50. Dinno A. Nonparametric Pairwise Multiple Comparisons in Independent Groups using Dunn’s Test. Stata J. 2015;15(1):292–300.
- View Article
- Google Scholar
51. Benjamini: Controlling the false discovery rate:… - Google Scholar [cited 10 Aug 2025]. Available from: https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20Royal%20Statistical%20Society%20Series%20B:%20Statistical%20Methodology&title=Controlling%20the%20false%20discovery%20rate:%20a%20practical%20and%20powerful%20approach%20to%20multiple%20testing&author=Yoav%20Benjamini&author=Yosef%20Hochberg&volume=57&issue=1&publication_year=1995&pages=289-300&
52. Sprent P. An Introduction to Categorical Data Analysis. J R Stat Soc Ser A Stat Soc. 2007;170(4):1178.
- View Article
- Google Scholar
53. Amazon.com: Modern Statistics with R: From Wrangling and Exploring Data to Inference and Predictive Modelling: 9781032512440: Thulin, Måns: Books. [cited 14 Aug 2025]. Available from: https://www.amazon.com/Modern-Statistics-Wrangling-Exploring-Predictive/dp/103251244X
54. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992;11(14–15):1825–39. pmid:1480876
- View Article
- PubMed/NCBI
- Google Scholar
55. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–15. pmid:20961685
- View Article
- PubMed/NCBI
- Google Scholar
56. Nijs J, Meeus M, Van Oosterwijck J, Ickmans K, Moorkens G, Hans G, et al. In the mind or in the brain? Scientific evidence for central sensitisation in chronic fatigue syndrome. Eur J Clin Invest. 2012;42(2):203–12. pmid:21793823
- View Article
- PubMed/NCBI
- Google Scholar
57. Novak P, Marciano SP, Witte A. Erratum: Role of Central Sensitization Syndrome in Patients With Autonomic Symptoms. Neurol Clin Pract. 2025;15(4):e200490. pmid:40510871
- View Article
- PubMed/NCBI
- Google Scholar
58. Goudman L, De Smedt A, Noppen M, Moens M. Is Central Sensitisation the Missing Link of Persisting Symptoms after COVID-19 Infection?. J Clin Med. 2021;10(23):5594. pmid:34884296
- View Article
- PubMed/NCBI
- Google Scholar
59. Di Stefano G, Celletti C, Baron R, Castori M, Di Franco M, La Cesa S, et al. Central sensitization as the mechanism underlying pain in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Eur J Pain. 2016;20(8):1319–25. pmid:26919608
- View Article
- PubMed/NCBI
- Google Scholar
60. Coelho FMS, de Carvalho Cremaschi RM, Novak P. Cerebral blood flow and end-tidal CO2 predict lightheadedness during head-up tilt in patients with orthostatic intolerance. Neurol Sci. 2024;45(12):5771–8. pmid:38980457
- View Article
- PubMed/NCBI
- Google Scholar
61. Novak V, Spies JM, Novak P, McPhee BR, Rummans TA, Low PA. Hypocapnia and cerebral hypoperfusion in orthostatic intolerance. Stroke. 1998;29(9):1876–81. pmid:9731612
- View Article
- PubMed/NCBI
- Google Scholar
62. Ocon AJ, Medow MS, Taneja I, Clarke D, Stewart JM. Decreased upright cerebral blood flow and cerebral autoregulation in normocapnic postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. 2009;297(2):H664-73. pmid:19502561
- View Article
- PubMed/NCBI
- Google Scholar
63. Immink RV, Pott FC, Secher NH, van Lieshout JJ. Hyperventilation, cerebral perfusion, and syncope. J Appl Physiol (1985). 2014;116(7):844–51. pmid:24265279
- View Article
- PubMed/NCBI
- Google Scholar
64. Lu Y, Yi L, Liu D, Li J, Sun L, Zhang Z. Alkalosis leads to the over-activity of cortical principal neurons. Neurosci Lett. 2012;525(2):117–22. pmid:22842394
- View Article
- PubMed/NCBI
- Google Scholar
65. Kim WSH, Ji X, Roudaia E, Chen JJ, Gilboa A, Sekuler A, et al. MRI Assessment of Cerebral Blood Flow in Nonhospitalized Adults Who Self-Isolated Due to COVID-19. J Magn Reson Imaging. 2023;58(2):593–602. pmid:36472248
- View Article
- PubMed/NCBI
- Google Scholar
66. van der Knaap N, Ariës MJH, van der Horst ICC, Jansen JFA. On the merits and potential of advanced neuroimaging techniques in COVID-19: A scoping review. Neuroimage Clin. 2024;42:103589. pmid:38461701
- View Article
- PubMed/NCBI
- Google Scholar
67. Ajčević M, Iscra K, Furlanis G, Michelutti M, Miladinović A, Buoite Stella A, et al. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci Rep. 2023;13(1):5808. pmid:37037833
- View Article
- PubMed/NCBI
- Google Scholar
68. Martelli D, Silvani A, McAllen RM, May CN, Ramchandra R. The low frequency power of heart rate variability is neither a measure of cardiac sympathetic tone nor of baroreflex sensitivity. Am J Physiol Heart Circ Physiol. 2014;307(7):H1005-12. pmid:25063795
- View Article
- PubMed/NCBI
- Google Scholar
69. Maclachlan L, Watson S, Gallagher P, Finkelmeyer A, Jason LA, Sunnquist M, et al. Are current chronic fatigue syndrome criteria diagnosing different disease phenotypes?. PLoS One. 2017;12(10):e0186885. pmid:29053742
- View Article
- PubMed/NCBI
- Google Scholar
70. Eldokla AM, Ali ST. Autonomic function testing in long-COVID syndrome patients with orthostatic intolerance. Auton Neurosci. 2022;241:102997. pmid:35679657
- View Article
- PubMed/NCBI
- Google Scholar
71. Shouman K, Vanichkachorn G, Cheshire WP, Suarez MD, Shelly S, Lamotte GJ, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31(3):385–94. pmid:33860871
- View Article
- PubMed/NCBI
- Google Scholar
72. Hira R, Karalasingham K, Baker JR, Raj SR. Autonomic Manifestations of Long-COVID Syndrome. Curr Neurol Neurosci Rep. 2023;23(12):881–92. pmid:37947962
- View Article
- PubMed/NCBI
- Google Scholar
73. Novak P, Giannetti MP, Weller E, Hamilton MJ, Mukerji SS, Alabsi HS, et al. Network autonomic analysis of post-acute sequelae of COVID-19 and postural tachycardia syndrome. Neurol Sci. 2022;43(12):6627–38. pmid:36169757
- View Article
- PubMed/NCBI
- Google Scholar
74. Stelfox HT, Ahmed SB, Ribeiro RA, Gettings EM, Pomerantsev E, Schmidt U. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med. 2006;34(4):1243–6. pmid:16484893
- View Article
- PubMed/NCBI
- Google Scholar
75. Fleischer M, Szepanowski F, Mausberg AK, Asan L, Uslar E, Zwanziger D, et al. Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19. Ther Adv Neurol Disord. 2024;17:17562864241229567. pmid:38348267
- View Article
- PubMed/NCBI
- Google Scholar
76. Goldstein DS, Cheshire WP. Roles of catechol neurochemistry in autonomic function testing. Clin Auton Res. 2018;28(3):273–88. pmid:29705971
- View Article
- PubMed/NCBI
- Google Scholar
77. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331–49. pmid:15317907
- View Article
- PubMed/NCBI
- Google Scholar
78. Kanczkowski W, Beuschlein F, Bornstein SR. Is there a role for the adrenal glands in long COVID?. Nat Rev Endocrinol. 2022;18(8):451–2. pmid:35637413
- View Article
- PubMed/NCBI
- Google Scholar
79. Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M, Hale TM, et al. The Hypothalamic-Pituitary-Adrenal Axis: Development, Programming Actions of Hormones, and Maternal-Fetal Interactions. Front Behav Neurosci. 2021;14:601939. pmid:33519393
- View Article
- PubMed/NCBI
- Google Scholar
80. Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015;1(1):e1400121. pmid:26079000
- View Article
- PubMed/NCBI
- Google Scholar
81. Serrador JM, Picot PA, Rutt BK, Shoemaker JK, Bondar RL. MRI measures of middle cerebral artery diameter in conscious humans during simulated orthostasis. Stroke. 2000;31(7):1672–8. pmid:10884472
- View Article
- PubMed/NCBI
- Google Scholar

[ref1] 1. Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. Front Med (Lausanne). 2023;10:1187163. pmid:37342500
View Article
PubMed/NCBI
Google Scholar

[2] View Article

[3] PubMed/NCBI

[4] Google Scholar

[ref2] 2. Grach SL, Seltzer J, Chon TY, Ganesh R. Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Mayo Clin Proc. 2023;98(10):1544–51. pmid:37793728
View Article
PubMed/NCBI
Google Scholar

[6] View Article

[7] PubMed/NCBI

[8] Google Scholar

[ref3] 3. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, et al. Multisystem Involvement in Post-Acute Sequelae of Coronavirus Disease 19. Ann Neurol. 2022;91(3):367–79. pmid:34952975
View Article
PubMed/NCBI
Google Scholar

[10] View Article

[11] PubMed/NCBI

[12] Google Scholar

[ref4] 4. Komaroff AL, Dantzer R. Causes of symptoms and symptom persistence in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. Cell Rep Med. 2025;6(8):102259. pmid:40744021
View Article
PubMed/NCBI
Google Scholar

[14] View Article

[15] PubMed/NCBI

[16] Google Scholar

[ref5] 5. Powers JP, McIntee TJ, Bhatia A, Madlock-Brown CR, Seltzer J, Sekar A, et al. Identifying commonalities and differences between EHR representations of PASC and ME/CFS in the RECOVER EHR cohort. Commun Med (Lond). 2025;5(1):109. pmid:40210986
View Article
PubMed/NCBI
Google Scholar

[18] View Article

[19] PubMed/NCBI

[20] Google Scholar

[ref6] 6. Wong TL, Weitzer DJ. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology. Medicina (Kaunas). 2021;57(5):418. pmid:33925784
View Article
PubMed/NCBI
Google Scholar

[22] View Article

[23] PubMed/NCBI

[24] Google Scholar

[ref7] 7. Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA. 2023;329(22):1934–46. pmid:37278994
View Article
PubMed/NCBI
Google Scholar

[26] View Article

[27] PubMed/NCBI

[28] Google Scholar

[ref8] 8. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany. PLoS Med. 2022;19(11):e1004122. pmid:36355754
View Article
PubMed/NCBI
Google Scholar

[30] View Article

[31] PubMed/NCBI

[32] Google Scholar

[ref9] 9. Makhluf H, Madany H, Kim K. Long COVID: Long-Term Impact of SARS-CoV2. Diagnostics (Basel). 2024;14(7):711. pmid:38611624
View Article
PubMed/NCBI
Google Scholar

[34] View Article

[35] PubMed/NCBI

[36] Google Scholar

[ref10] 10. Evengård B, Jonzon E, Sandberg A, Theorell T, Lindh G. Differences between patients with chronic fatigue syndrome and with chronic fatigue at an infectious disease clinic in Stockholm, Sweden. Psychiatry Clin Neurosci. 2003;57(4):361–8. pmid:12839515
View Article
PubMed/NCBI
Google Scholar

[38] View Article

[39] PubMed/NCBI

[40] Google Scholar

[ref11] 11. Walitt B, Singh K, LaMunion SR, Hallett M, Jacobson S, Chen K, et al. Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nat Commun. 2024;15(1):907. pmid:38383456
View Article
PubMed/NCBI
Google Scholar

[42] View Article

[43] PubMed/NCBI

[44] Google Scholar

[ref12] 12. Eckey M, Li P, Morrison B, Bergquist J, Davis RW, Xiao W. Patient-reported treatment outcomes in ME/CFS and long COVID. Proc Natl Acad Sci U S A. 2025;122(28):e2426874122. pmid:40627388
View Article
PubMed/NCBI
Google Scholar

[46] View Article

[47] PubMed/NCBI

[48] Google Scholar

[ref13] 13. Nelson MJ, Bahl JS, Buckley JD, Thomson RL, Davison K. Evidence of altered cardiac autonomic regulation in myalgic encephalomyelitis/chronic fatigue syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(43):e17600. pmid:31651868
View Article
PubMed/NCBI
Google Scholar

[50] View Article

[51] PubMed/NCBI

[52] Google Scholar

[ref14] 14. Ormiston CK, Świątkiewicz I, Taub PR. Postural orthostatic tachycardia syndrome as a sequela of COVID-19. Heart Rhythm. 2022;19(11):1880–9. pmid:35853576
View Article
PubMed/NCBI
Google Scholar

[54] View Article

[55] PubMed/NCBI

[56] Google Scholar

[ref15] 15. Stewart JM. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res. 2000;48(2):218–26. pmid:10926298
View Article
PubMed/NCBI
Google Scholar

[58] View Article

[59] PubMed/NCBI

[60] Google Scholar

[ref16] 16. van Campen CLMC, Rowe PC, Visser FC. Orthostatic Symptoms and Reductions in Cerebral Blood Flow in Long-Haul COVID-19 Patients: Similarities with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Medicina (Kaunas). 2021;58(1):28. pmid:35056336
View Article
PubMed/NCBI
Google Scholar

[62] View Article

[63] PubMed/NCBI

[64] Google Scholar

[ref17] 17. Novak P, Mukerji SS, Alabsi HS, Systrom D, Marciano SP, Felsenstein D, et al. Multisystem Involvement in Post-Acute Sequelae of Coronavirus Disease 19. Ann Neurol. 2022;91(3):367–79. pmid:34952975
View Article
PubMed/NCBI
Google Scholar

[66] View Article

[67] PubMed/NCBI

[68] Google Scholar

[ref18] 18. Joseph P, Arevalo C, Oliveira RKF, Faria-Urbina M, Felsenstein D, Oaklander AL, et al. Insights From Invasive Cardiopulmonary Exercise Testing of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Chest. 2021;160(2):642–51. pmid:33577778
View Article
PubMed/NCBI
Google Scholar

[70] View Article

[71] PubMed/NCBI

[72] Google Scholar

[ref19] 19. Hakim A, De Wandele I, O’Callaghan C, Pocinki A, Rowe P. Chronic fatigue in Ehlers-Danlos syndrome-Hypermobile type. Am J Med Genet C Semin Med Genet. 2017;175(1):175–80. pmid:28186393
View Article
PubMed/NCBI
Google Scholar

[74] View Article

[75] PubMed/NCBI

[76] Google Scholar

[ref20] 20. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72. pmid:21431947
View Article
PubMed/NCBI
Google Scholar

[78] View Article

[79] PubMed/NCBI

[80] Google Scholar

[ref21] 21. Natelson BH, Intriligator R, Cherniack NS, Chandler HK, Stewart JM. Hypocapnia is a biological marker for orthostatic intolerance in some patients with chronic fatigue syndrome. Dyn Med. 2007;6:2. pmid:17263876
View Article
PubMed/NCBI
Google Scholar

[82] View Article

[83] PubMed/NCBI

[84] Google Scholar

[ref22] 22. Novak P. Autonomic Testing. Oxford University Press; 2019.

[ref23] 23. Novak P. Orthostatic Cerebral Hypoperfusion Syndrome. Front Aging Neurosci. 2016;8:22. pmid:26909037
View Article
PubMed/NCBI
Google Scholar

[87] View Article

[88] PubMed/NCBI

[89] Google Scholar

[ref24] 24. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–7. pmid:34951953
View Article
PubMed/NCBI
Google Scholar

[91] View Article

[92] PubMed/NCBI

[93] Google Scholar

[ref25] 25. CDC. COVID Data Tracker. In: Centers for Disease Control and Prevention [Internet]. 2020 [cited 22 Aug 2024]. Available from: https://covid.cdc.gov/covid-data-tracker

[ref26] 26. Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. Myalgic encephalomyelitis: International Consensus Criteria. J Intern Med. 2011;270(4):327–38. pmid:21777306
View Article
PubMed/NCBI
Google Scholar

[96] View Article

[97] PubMed/NCBI

[98] Google Scholar

[ref27] 27. Bateman L, Bested AC, Bonilla HF, Chheda BV, Chu L, Curtin JM, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management. Mayo Clin Proc. 2021;96(11):2861–78. pmid:34454716
View Article
PubMed/NCBI
Google Scholar

[100] View Article

[101] PubMed/NCBI

[102] Google Scholar

[ref28] 28. Novak P. Assessment of sympathetic index from the Valsalva maneuver. Neurology. 2011;76(23):2010–6. pmid:21646629
View Article
PubMed/NCBI
Google Scholar

[104] View Article

[105] PubMed/NCBI

[106] Google Scholar

[ref29] 29. Gensemer C, Burks R, Kautz S, Judge DP, Lavallee M, Norris RA. Hypermobile Ehlers-Danlos syndromes: Complex phenotypes, challenging diagnoses, and poorly understood causes. Dev Dyn. 2021;250(3):318–44. pmid:32629534
View Article
PubMed/NCBI
Google Scholar

[108] View Article

[109] PubMed/NCBI

[110] Google Scholar

[ref30] 30. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet. 1998;77(1):31–7.
View Article
Google Scholar

[112] View Article

[113] Google Scholar

[ref31] 31. Malfait F, Francomano C, Byers P, Belmont J, Berglund B, Black J, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. pmid:28306229
View Article
PubMed/NCBI
Google Scholar

[115] View Article

[116] PubMed/NCBI

[117] Google Scholar

[ref32] 32. Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, et al. Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology. 2011;76(12):1099–105. pmid:21422460
View Article
PubMed/NCBI
Google Scholar

[119] View Article

[120] PubMed/NCBI

[121] Google Scholar

[ref33] 33. Bastyr EJ 3rd, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005;27(8):1278–94. pmid:16199253
View Article
PubMed/NCBI
Google Scholar

[123] View Article

[124] PubMed/NCBI

[125] Google Scholar

[ref34] 34. Cook KF, Dunn W, Griffith JW, Morrison MT, Tanquary J, Sabata D, et al. Pain assessment using the NIH Toolbox. Neurology. 2013;80(11 Suppl 3):S49-53. pmid:23479545
View Article
PubMed/NCBI
Google Scholar

[127] View Article

[128] PubMed/NCBI

[129] Google Scholar

[ref35] 35. Boonstra AM, Stewart RE, Köke AJA, Oosterwijk RFA, Swaan JL, Schreurs KMG, et al. Cut-Off Points for Mild, Moderate, and Severe Pain on the Numeric Rating Scale for Pain in Patients with Chronic Musculoskeletal Pain: Variability and Influence of Sex and Catastrophizing. Front Psychol. 2016;7:1466. pmid:27746750
View Article
PubMed/NCBI
Google Scholar

[131] View Article

[132] PubMed/NCBI

[133] Google Scholar

[ref36] 36. Neblett R, Hartzell MM, Mayer TG, Cohen H, Gatchel RJ. Establishing Clinically Relevant Severity Levels for the Central Sensitization Inventory. Pain Pract. 2017;17(2):166–75. pmid:26989894
View Article
PubMed/NCBI
Google Scholar

[135] View Article

[136] PubMed/NCBI

[137] Google Scholar

[ref37] 37. Novak P. Electrochemical skin conductance: a systematic review. Clin Auton Res. 2019;29(1):17–29. pmid:28951985
View Article
PubMed/NCBI
Google Scholar

[139] View Article

[140] PubMed/NCBI

[141] Google Scholar

[ref38] 38. Novak P. Electrochemical Skin Conductance Correlates with Skin Nerve Fiber Density. Front Aging Neurosci. 2016;8:199. pmid:27605912
View Article
PubMed/NCBI
Google Scholar

[143] View Article

[144] PubMed/NCBI

[145] Google Scholar

[ref39] 39. Maron BA, Cockrill BA, Waxman AB, Systrom DM. The invasive cardiopulmonary exercise test. Circulation. 2013;127(10):1157–64. pmid:23479667
View Article
PubMed/NCBI
Google Scholar

[147] View Article

[148] PubMed/NCBI

[149] Google Scholar

[ref40] 40. Singh I, Joseph P, Heerdt PM, Cullinan M, Lutchmansingh DD, Gulati M, et al. Persistent Exertional Intolerance After COVID-19: Insights From Invasive Cardiopulmonary Exercise Testing. Chest. 2022;161(1):54–63. pmid:34389297
View Article
PubMed/NCBI
Google Scholar

[151] View Article

[152] PubMed/NCBI

[153] Google Scholar

[ref41] 41. Devigili G, Tugnoli V, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131(Pt 7):1912–25. pmid:18524793
View Article
PubMed/NCBI
Google Scholar

[155] View Article

[156] PubMed/NCBI

[157] Google Scholar

[ref42] 42. Farhad K. Current Diagnosis and Treatment of Painful Small Fiber Neuropathy. Curr Neurol Neurosci Rep. 2019;19(12):103. pmid:31773305
View Article
PubMed/NCBI
Google Scholar

[159] View Article

[160] PubMed/NCBI

[161] Google Scholar

[ref43] 43. Novak P. Qpack-a Python package for QASAT-quantitative scale for grading cerebral blood flow, autonomic testing, and skin biopsies. Neurol Sci. 2022;43(8):4821–8. pmid:35347527
View Article
PubMed/NCBI
Google Scholar

[163] View Article

[164] PubMed/NCBI

[165] Google Scholar

[ref44] 44. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–32. pmid:31806905
View Article
PubMed/NCBI
Google Scholar

[167] View Article

[168] PubMed/NCBI

[169] Google Scholar

[ref45] 45. Levine TD, Kafaie J, Zeidman LA, Saperstein DS, Massaquoi R, Bland RJ, et al. Cryptogenic small-fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor receptor-3. Muscle Nerve. 2020;61(4):512–5. pmid:31650561
View Article
PubMed/NCBI
Google Scholar

[171] View Article

[172] PubMed/NCBI

[173] Google Scholar

[ref46] 46. Shouman K, Sandroni P. Antibody Testing for Suspected Autoimmune Autonomic Dysfunction and Small Fiber Neuropathies. J Clin Neurophysiol. 2021;38(4):274–8. pmid:34009850
View Article
PubMed/NCBI
Google Scholar

[175] View Article

[176] PubMed/NCBI

[177] Google Scholar

[ref47] 47. Medic Spahic J, Ricci F, Aung N, Hallengren E, Axelsson J, Hamrefors V, et al. Proteomic analysis reveals sex-specific biomarker signature in postural orthostatic tachycardia syndrome. BMC Cardiovasc Disord. 2020;20(1):190. pmid:32321428
View Article
PubMed/NCBI
Google Scholar

[179] View Article

[180] PubMed/NCBI

[181] Google Scholar

[ref48] 48. Zhong J-H, Huang D-H, Chen Z-Y. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(43):75381–8. pmid:29088873
View Article
PubMed/NCBI
Google Scholar

[183] View Article

[184] PubMed/NCBI

[185] Google Scholar

[ref49] 49. Hecke TV. Power study of anova versus Kruskal-Wallis test. J Stat Manag Syst. 2012;15(2–3):241–7.
View Article
Google Scholar

[187] View Article

[188] Google Scholar

[ref50] 50. Dinno A. Nonparametric Pairwise Multiple Comparisons in Independent Groups using Dunn’s Test. Stata J. 2015;15(1):292–300.
View Article
Google Scholar

[190] View Article

[191] Google Scholar

[ref51] 51. Benjamini: Controlling the false discovery rate:… - Google Scholar [cited 10 Aug 2025]. Available from: https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20Royal%20Statistical%20Society%20Series%20B:%20Statistical%20Methodology&title=Controlling%20the%20false%20discovery%20rate:%20a%20practical%20and%20powerful%20approach%20to%20multiple%20testing&author=Yoav%20Benjamini&author=Yosef%20Hochberg&volume=57&issue=1&publication_year=1995&pages=289-300&

[ref52] 52. Sprent P. An Introduction to Categorical Data Analysis. J R Stat Soc Ser A Stat Soc. 2007;170(4):1178.
View Article
Google Scholar

[194] View Article

[195] Google Scholar

[ref53] 53. Amazon.com: Modern Statistics with R: From Wrangling and Exploring Data to Inference and Predictive Modelling: 9781032512440: Thulin, Måns: Books. [cited 14 Aug 2025]. Available from: https://www.amazon.com/Modern-Statistics-Wrangling-Exploring-Predictive/dp/103251244X

[ref54] 54. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992;11(14–15):1825–39. pmid:1480876
View Article
PubMed/NCBI
Google Scholar

[198] View Article

[199] PubMed/NCBI

[200] Google Scholar

[ref55] 55. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2–15. pmid:20961685
View Article
PubMed/NCBI
Google Scholar

[202] View Article

[203] PubMed/NCBI

[204] Google Scholar

[ref56] 56. Nijs J, Meeus M, Van Oosterwijck J, Ickmans K, Moorkens G, Hans G, et al. In the mind or in the brain? Scientific evidence for central sensitisation in chronic fatigue syndrome. Eur J Clin Invest. 2012;42(2):203–12. pmid:21793823
View Article
PubMed/NCBI
Google Scholar

[206] View Article

[207] PubMed/NCBI

[208] Google Scholar

[ref57] 57. Novak P, Marciano SP, Witte A. Erratum: Role of Central Sensitization Syndrome in Patients With Autonomic Symptoms. Neurol Clin Pract. 2025;15(4):e200490. pmid:40510871
View Article
PubMed/NCBI
Google Scholar

[210] View Article

[211] PubMed/NCBI

[212] Google Scholar

[ref58] 58. Goudman L, De Smedt A, Noppen M, Moens M. Is Central Sensitisation the Missing Link of Persisting Symptoms after COVID-19 Infection?. J Clin Med. 2021;10(23):5594. pmid:34884296
View Article
PubMed/NCBI
Google Scholar

[214] View Article

[215] PubMed/NCBI

[216] Google Scholar

[ref59] 59. Di Stefano G, Celletti C, Baron R, Castori M, Di Franco M, La Cesa S, et al. Central sensitization as the mechanism underlying pain in joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Eur J Pain. 2016;20(8):1319–25. pmid:26919608
View Article
PubMed/NCBI
Google Scholar

[218] View Article

[219] PubMed/NCBI

[220] Google Scholar

[ref60] 60. Coelho FMS, de Carvalho Cremaschi RM, Novak P. Cerebral blood flow and end-tidal CO2 predict lightheadedness during head-up tilt in patients with orthostatic intolerance. Neurol Sci. 2024;45(12):5771–8. pmid:38980457
View Article
PubMed/NCBI
Google Scholar

[222] View Article

[223] PubMed/NCBI

[224] Google Scholar

[ref61] 61. Novak V, Spies JM, Novak P, McPhee BR, Rummans TA, Low PA. Hypocapnia and cerebral hypoperfusion in orthostatic intolerance. Stroke. 1998;29(9):1876–81. pmid:9731612
View Article
PubMed/NCBI
Google Scholar

[226] View Article

[227] PubMed/NCBI

[228] Google Scholar

[ref62] 62. Ocon AJ, Medow MS, Taneja I, Clarke D, Stewart JM. Decreased upright cerebral blood flow and cerebral autoregulation in normocapnic postural tachycardia syndrome. Am J Physiol Heart Circ Physiol. 2009;297(2):H664-73. pmid:19502561
View Article
PubMed/NCBI
Google Scholar

[230] View Article

[231] PubMed/NCBI

[232] Google Scholar

[ref63] 63. Immink RV, Pott FC, Secher NH, van Lieshout JJ. Hyperventilation, cerebral perfusion, and syncope. J Appl Physiol (1985). 2014;116(7):844–51. pmid:24265279
View Article
PubMed/NCBI
Google Scholar

[234] View Article

[235] PubMed/NCBI

[236] Google Scholar

[ref64] 64. Lu Y, Yi L, Liu D, Li J, Sun L, Zhang Z. Alkalosis leads to the over-activity of cortical principal neurons. Neurosci Lett. 2012;525(2):117–22. pmid:22842394
View Article
PubMed/NCBI
Google Scholar

[238] View Article

[239] PubMed/NCBI

[240] Google Scholar

[ref65] 65. Kim WSH, Ji X, Roudaia E, Chen JJ, Gilboa A, Sekuler A, et al. MRI Assessment of Cerebral Blood Flow in Nonhospitalized Adults Who Self-Isolated Due to COVID-19. J Magn Reson Imaging. 2023;58(2):593–602. pmid:36472248
View Article
PubMed/NCBI
Google Scholar

[242] View Article

[243] PubMed/NCBI

[244] Google Scholar

[ref66] 66. van der Knaap N, Ariës MJH, van der Horst ICC, Jansen JFA. On the merits and potential of advanced neuroimaging techniques in COVID-19: A scoping review. Neuroimage Clin. 2024;42:103589. pmid:38461701
View Article
PubMed/NCBI
Google Scholar

[246] View Article

[247] PubMed/NCBI

[248] Google Scholar

[ref67] 67. Ajčević M, Iscra K, Furlanis G, Michelutti M, Miladinović A, Buoite Stella A, et al. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci Rep. 2023;13(1):5808. pmid:37037833
View Article
PubMed/NCBI
Google Scholar

[250] View Article

[251] PubMed/NCBI

[252] Google Scholar

[ref68] 68. Martelli D, Silvani A, McAllen RM, May CN, Ramchandra R. The low frequency power of heart rate variability is neither a measure of cardiac sympathetic tone nor of baroreflex sensitivity. Am J Physiol Heart Circ Physiol. 2014;307(7):H1005-12. pmid:25063795
View Article
PubMed/NCBI
Google Scholar

[254] View Article

[255] PubMed/NCBI

[256] Google Scholar

[ref69] 69. Maclachlan L, Watson S, Gallagher P, Finkelmeyer A, Jason LA, Sunnquist M, et al. Are current chronic fatigue syndrome criteria diagnosing different disease phenotypes?. PLoS One. 2017;12(10):e0186885. pmid:29053742
View Article
PubMed/NCBI
Google Scholar

[258] View Article

[259] PubMed/NCBI

[260] Google Scholar

[ref70] 70. Eldokla AM, Ali ST. Autonomic function testing in long-COVID syndrome patients with orthostatic intolerance. Auton Neurosci. 2022;241:102997. pmid:35679657
View Article
PubMed/NCBI
Google Scholar

[262] View Article

[263] PubMed/NCBI

[264] Google Scholar

[ref71] 71. Shouman K, Vanichkachorn G, Cheshire WP, Suarez MD, Shelly S, Lamotte GJ, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res. 2021;31(3):385–94. pmid:33860871
View Article
PubMed/NCBI
Google Scholar

[266] View Article

[267] PubMed/NCBI

[268] Google Scholar

[ref72] 72. Hira R, Karalasingham K, Baker JR, Raj SR. Autonomic Manifestations of Long-COVID Syndrome. Curr Neurol Neurosci Rep. 2023;23(12):881–92. pmid:37947962
View Article
PubMed/NCBI
Google Scholar

[270] View Article

[271] PubMed/NCBI

[272] Google Scholar

[ref73] 73. Novak P, Giannetti MP, Weller E, Hamilton MJ, Mukerji SS, Alabsi HS, et al. Network autonomic analysis of post-acute sequelae of COVID-19 and postural tachycardia syndrome. Neurol Sci. 2022;43(12):6627–38. pmid:36169757
View Article
PubMed/NCBI
Google Scholar

[274] View Article

[275] PubMed/NCBI

[276] Google Scholar

[ref74] 74. Stelfox HT, Ahmed SB, Ribeiro RA, Gettings EM, Pomerantsev E, Schmidt U. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med. 2006;34(4):1243–6. pmid:16484893
View Article
PubMed/NCBI
Google Scholar

[278] View Article

[279] PubMed/NCBI

[280] Google Scholar

[ref75] 75. Fleischer M, Szepanowski F, Mausberg AK, Asan L, Uslar E, Zwanziger D, et al. Cytokines (IL1β, IL6, TNFα) and serum cortisol levels may not constitute reliable biomarkers to identify individuals with post-acute sequelae of COVID-19. Ther Adv Neurol Disord. 2024;17:17562864241229567. pmid:38348267
View Article
PubMed/NCBI
Google Scholar

[282] View Article

[283] PubMed/NCBI

[284] Google Scholar

[ref76] 76. Goldstein DS, Cheshire WP. Roles of catechol neurochemistry in autonomic function testing. Clin Auton Res. 2018;28(3):273–88. pmid:29705971
View Article
PubMed/NCBI
Google Scholar

[286] View Article

[287] PubMed/NCBI

[288] Google Scholar

[ref77] 77. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004;56(3):331–49. pmid:15317907
View Article
PubMed/NCBI
Google Scholar

[290] View Article

[291] PubMed/NCBI

[292] Google Scholar

[ref78] 78. Kanczkowski W, Beuschlein F, Bornstein SR. Is there a role for the adrenal glands in long COVID?. Nat Rev Endocrinol. 2022;18(8):451–2. pmid:35637413
View Article
PubMed/NCBI
Google Scholar

[294] View Article

[295] PubMed/NCBI

[296] Google Scholar

[ref79] 79. Sheng JA, Bales NJ, Myers SA, Bautista AI, Roueinfar M, Hale TM, et al. The Hypothalamic-Pituitary-Adrenal Axis: Development, Programming Actions of Hormones, and Maternal-Fetal Interactions. Front Behav Neurosci. 2021;14:601939. pmid:33519393
View Article
PubMed/NCBI
Google Scholar

[298] View Article

[299] PubMed/NCBI

[300] Google Scholar

[ref80] 80. Hornig M, Montoya JG, Klimas NG, Levine S, Felsenstein D, Bateman L, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015;1(1):e1400121. pmid:26079000
View Article
PubMed/NCBI
Google Scholar

[302] View Article

[303] PubMed/NCBI

[304] Google Scholar

[ref81] 81. Serrador JM, Picot PA, Rutt BK, Shoemaker JK, Bondar RL. MRI measures of middle cerebral artery diameter in conscious humans during simulated orthostasis. Stroke. 2000;31(7):1672–8. pmid:10884472
View Article
PubMed/NCBI
Google Scholar

[306] View Article

[307] PubMed/NCBI

[308] Google Scholar

Figures

Abstract

Introduction

Materials and methods

Results

Conclusion

Introduction

Materials and methods

Standard protocol approvals, registrations, and patient consent

Clinical definitions

Inclusion and exclusion criteria

Inclusion criteria.

Exclusion criteria.

Patient reported surveys

Autonomic testing

Skin biopsies

Criteria for small fiber neuropathy

Grading of autonomic tests

Laboratory and inflammation markers

Statistical analysis

Statistical power

Results

Symptoms

Autonomic testing

QASAT

Invasive cardiopulmonary exercise testing (iCPET)

Discussion

Comparing Long COVID with ME/CFS

Central sensitization

Cerebral blood flow

Autonomic features

Skin biopsies

Inflammatory, metabolic, and hormonal markers

Comparisons of Long COVID/ME/CFS to hEDS

Study limitations

Conclusion

Acknowledgments

References